Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Reexamination Certificate
2007-06-12
2007-06-12
Saunders, David A. (Department: 1644)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
C424S001530, C424S001690, C530S391500
Reexamination Certificate
active
11181811
ABSTRACT:
Methods and kits for radiolabeling proteins, peptides and ligands with radiolytic isotopes, particularly yttrium-90, are disclosed, whereby sufficient purity, specific activity and binding affinity are achieved such that the radiolabeled protein may be directly administered to a patient without further column purification. Such kits and methods will be particularly useful in bringing radioimmunotherapy to the hospital and outpatient setting for the treatment of cancer.
REFERENCES:
patent: 4401592 (1983-08-01), Yoshikumi et al.
patent: 4636380 (1987-01-01), Wong
patent: 4816567 (1989-03-01), Cabilly
patent: 5124471 (1992-06-01), Gansow et al.
patent: 5434287 (1995-07-01), Gansow et al.
patent: 5460785 (1995-10-01), Rhodes
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5541287 (1996-07-01), Yau
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5728369 (1998-03-01), Griffiths
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5766751 (1998-06-01), Kotani et al.
patent: 5820845 (1998-10-01), Dean et al.
patent: 5830431 (1998-11-01), Srinivasan et al.
patent: 5874540 (1999-02-01), Hansen et al.
patent: 6994840 (2006-02-01), Chinn
patent: 0 274 394 (1988-07-01), None
patent: 0 529 645 (1993-03-01), None
patent: WO 88/04936 (1988-07-01), None
patent: WO 92/07466 (1992-05-01), None
patent: WO 94 11026 (1994-05-01), None
patent: WO 96/14879 (1996-05-01), None
Gansow et al., Advanced Methods for Radiolabeling Monoclonal Antibodies with Therapeutic Radionuclides,Cancer Therapy With Radiolabelled Antibodies, 1995, Chpater 6, pp. 63-76.
Gary L. Griffiths, Antibody Radiolabeling With Isotopes of Rhenium,Cancer Therapy With Radiolabelled Antibodies, 1995, Chapter 7, pp. 77-86.
Adams RA, “Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma,”Cancer Research, 1967, 27(1):2479-2482.
Adams RA, et al., “Direct implantation and transplantation of human acute lymphoblastic leukemia in hamsters, SB-2,” 1968,Cancer Research, 1968, 28:1121-1125.
Chakrabarti MC et al., “Prevention of radiolysis of monoclonal antibody during labeling,”J. Nucl. Med., 1996, 37(8):1384-88.
DeNardo et al., “Yttrium-90/Indium-111 DOTA peptide chimeric L6: pharmacokinetics, dosimetry and initial therapeutic studies in patients with breast cancer,” J. Nucl. Med., 1995, 36:97P.
Kozak RW, et al., “Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity,” Cancer Res., 1989, 49(10):2639-44.
Leland JK, et al., “Electrogenerated chemiluminescence: An oxidative-reduction type ECL reaction sequence using Tripropyl Amine,”Electrochem. Soc., 1990, 137, 3127.
Lewis et al., “A facile, water-soluble method for modification of proteins with DOTA,”Bioconj Chem., 1994, 5:565-76.
Lindmo T, et al., “Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess,” J Immunol Methods, 1984, 72(1):77-89.
Liu AY, et al., “Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity,” J. Immunol., 1987, 139/10:3521-26.
Mather SJ, et al., “Labeling monoclonal antibodies with yttrium-90,” Eur. J. Nucl. Med., 1989, 15;307-312.
Mirzadeh S., et al., “Radiometal labelling of immunoproteins: Covalent linkage of 2-(4-Isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin,”Bioconj Chemistry, 1990, 1(1):59.
Muller RJ, “Calculation of average antibody affinity in anti-hapten sera from data obtained by competitive radioimmunoassay,” J Immunol Methods, 1980, 34(4):345-52.
Parker BA, et al., “Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody,”Cancer Research, 1992, 50:1022s-28s.
Pietersz GA, et al., “The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer,” Immunol. Cell Biol., 1987, 65:111-125.
Pizzarello, Direct and indirect action. In Pizzarello and Witcofski, eds.Basic Radiation Biology, 2nded. Philadelphia: Lea & Febger, 1975, pp. 20-29.
Robinson, RD et al., “Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities,” Hum. Antibod. Hybridomas, 1991, 2:84-93.
Salako et al., “Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations,” J. Nucl. Med., 1998, 39:667-70.
Thomas et al., Gamma-interferon administration after 90Y radiolabeled antibody therapy: survival and hematopoietic toxicity studies,” Int. J. radiat. Oncol. Biol. Phys., 1995, 31:529-534.
Brechbiel MW, et al., “Synthesis of 1-(p-Isothiocyanatobenzyl) derivatives of DPTA and EDTA. Antibody labeling and tumor-imaging studies,”Inorganic Chemistry, 1986, 25(16):2772-81.
Chinol et al, “Generator-Produced Yttrium-90 for Radioimmunotherapy,” J. Nuclear Medicine, 1987, 28(9):1465-1470.
Hnatowich et al., “The Preparation of DTPA-Coupled Antibodies Radiolabeled with Metallic Radionuclides: an Improved Method,” J. Immunological Methods, 1983, 65:147-157.
Cytogen OncoScint Product Information, 1998, Internet document.
Richardson et al., Optimization and batch production of DTPA-labeled antibody kits for routine use in111in immunoscintography, Nuclear Medicine Communications, 1987, 8:346-356.
Goodwin et al., “Chelate Conjugates of Monoclonal Antibodies for Imaging Lymphoid Structures in the Mouse,” 1985, 26(5):493-498.
International Search Report for PCT/US00/05078, mailed Dec. 28, 2000.
International Preliminary Examination Report for PCT/US00/05078, mailed Jul. 12, 2001.
International Search Report for PCT/US00/05061, mailed Dec. 12, 2000.
International Preliminary Examination Report for PCT/US00/05061, mailed May 4, 2001.
Biogen Idec Inc.
Pillsbury Winthrop Shaw & Pittman LLP
Saunders David A.
LandOfFree
Method for radiolabeling antibodies with yttrium-90 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for radiolabeling antibodies with yttrium-90, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for radiolabeling antibodies with yttrium-90 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3882376